Following the late-stage failure of its lead program, an experimental gene therapy treatment for the most aggressive form of brain cancer, Tocagen will reduce its workforce by 65 percent, the company said Thursday.
The layoffs will result in a staff of about 30 people by year’s end, Tocagen (NASDAQ: TOCA) said in the press release.
CEO Marty Duvall said the company, with its remaining cash, will prioritize the completion of an analysis of the results from the trial, called Toca 5, and a presentation of that analysis late next month at the annual meeting of the Society For Neuro-Oncology, in… Read more »
UNDERWRITERS AND PARTNERS
